التفاصيل البيبلوغرافية
| العنوان: |
Preemptive Versus Reactive Topical Clobetasol for Regorafenib‐Induced Hand‐Foot Reactions: A Preplanned Analysis of the ReDOS Trial. |
| المؤلفون: |
Jatoi, Aminah, Ou, Fang‐Shu, Ahn, Daniel H., Zemla, Tyler J., Le‐Rademacher, Jennifer G., Boland, Patrick, Ciombor, Kristen K., Jacobs, Nisha L., Pasche, Boris, Cleary, James M., McCune, Jeannine S., Pedersen, Katrina S., Barzi, Afsaneh, Chiorean, E. Gabriela, Heying, Erica N., Lenz, Heinz‐Josef, Sloan, Jeff A., Grothey, Axel, Lacouture, Mario E., Bekaii‐Saab, Tanios |
| المصدر: |
Oncologist; Jul2021, Vol. 26 Issue 7, p610-618, 9p, 7 Charts, 1 Graph |
| مصطلحات موضوعية: |
HAND-foot syndrome, DRUG efficacy, ADRENOCORTICAL hormones, ANTI-inflammatory agents, ANTINEOPLASTIC agents, ACTIVITIES of daily living, HEALTH outcome assessment, COMPARATIVE studies, CANCER patients, DESCRIPTIVE statistics, QUALITY of life, CUTANEOUS therapeutics, SECONDARY analysis, EVALUATION |
| مستخلص: |
Background: Hand‐foot skin reaction (HFSR) is the most common regorafenib‐induced adverse event and is in need of effective prevention and palliation. Materials and Methods: The Regorafenib Dose Optimization Study (ReDOS), a four‐arm, previously published trial with a 1:1:1:1 randomization scheme, was analyzed in a manner in keeping with the original protocol to assess whether clobetasol 0.05% cream (a corticosteroid) applied to the palms and soles twice per day for 8 weeks was more effective when prescribed preemptively (before the development of HFSR) versus reactively (after the development of HFSR). Patients were assessed during the first two cycles of regorafenib. Results: Sixty‐one patients received preemptive clobetasol, and 55 received reactive clobetasol. Groups were balanced on demographics. Over the first two cycles, no evidence of HFSR occurred in 30% with preemptive clobetasol versus 13% with reactive clobetasol (p =.03). During the first cycle, 54% and 45% of patients had no HFSR with preemptive and reactive clobetasol, respectively (p =.35). During the second cycle, 33% and 15% had no HFSR with preemptive and reactive clobetasol, respectively (p =.02). During the second cycle, rates of grade 1, 2, and 3 HFSR were 30%, 8%, and 3%, respectively, with preemptive clobetasol and 43%, 18%, and 7%, respectively, with reactive clobetasol (p =.12). Patient‐reported outcomes showed HFSR compromised nearly all activities of daily living with worse quality of life in patients who received reactive versus preemptive clobetasol. No clobetasol‐induced adverse events were reported. Conclusion: Preemptive clobetasol might lessen regorafenib‐induced hand‐foot reactions compared with reactive therapy. Further confirmatory studies are needed in a larger patient cohort. Implications for Practice: Regorafenib causes hand‐foot skin reactions. Preemptive clobetasol, a high‐potency topical corticosteroid, appears to lessen the severity of this adverse event. Although further study is needed, the favorable adverse event profile of this intervention might prompt clinicians to discuss this option with their patients. Hand‐foot skin reaction is a common regorafenib‐induced adverse event. This article reports on the use of topical clobetasol and its role when administered preventively, before a skin reaction occurs. [ABSTRACT FROM AUTHOR] |
|
Copyright of Oncologist is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder